Radalbuvir Explained

Iupac Name:	5-(3,3-Dimethylbut-1-yn-1-yl)-3-thiophene-2-carboxylic acid
Width:	250
Legal Us:	Investigational New Drug
Cas Number:	1314795-11-3
Unii:	273K4V0SPC
Pubchem:	53259022
Chemspiderid:	31140180
Synonyms:	GS-9669
C:	30
H:	41
N:	1
O:	6
S:	1
Smiles:	CC1=CC[C@@H](CC1)C(=O)N([C@H]2CC[C@](CC2)(O)CO[C@@H]3COCC3)c4c(sc(c4)C#CC(C)(C)C)C(=O)O
Stdinchi:	1S/C30H41NO6S/c1-20-5-7-21(8-6-20)27(32)31(25-17-24(11-13-29(2,3)4)38-26(25)28(33)34)22-9-14-30(35,15-10-22)19-37-23-12-16-36-18-23/h5,17,21-23,35H,6-10,12,14-16,18-19H2,1-4H3,(H,33,34)/t21-,22-,23-,30+/m0/s1
Stdinchikey:	MUICUPWICXUNRS-GDCCIXDYSA-N

Radalbuvir (INN,^[1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials.^[2] It targets NS5B polymerase.^[3]

Notes and References

International Nonproprietary Names for Pharmaceutical Substances . https://web.archive.org/web/20150402090316/https://www.who.int/medicines/publications/druginformation/PL112-final.pdf . 2015-04-02 . WHO Drug Information . 28 . 4 . 2014.
Web site: Search of: GS-9669 — List Results. ClinicalTrials.gov.
Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR . NS5B polymerase inhibitors in phase II clinical trials for HCV infection . Expert Opinion on Investigational Drugs . 27 . 3 . 243–250 . March 2018 . 29271672 . 10.1080/13543784.2018.1420780 . 3672885 .